Co-Diagnostics, Inc. saw its shares retreat in premarket trading on Wednesday after the molecular diagnostics company announced a $3 million private placement late Tuesday. The news came on the heels of a 43.8% surge in the stock price to $1.97 during regular trading, driven by the completion of a development strategy for a Bundibugyo virus assay amid the ongoing Ebola outbreak in the Democratic Republic of Congo and Uganda. In after-hours activity, the stock fell 13.3% to $1.71, reflecting investor concerns over potential dilution and the company's cash position.
Private Placement Details
The company will sell 1.65 million shares or pre-funded warrants, along with warrants to purchase up to 3.29 million additional shares. Each unit, consisting of one share and one warrant, is priced at $1.821. The warrants carry an exercise price of $1.571 and a five-year term. The transaction is expected to close around May 21, subject to customary conditions, with Maxim Group serving as the sole placement agent. Based on the 3.60 million common shares outstanding as of May 12, the new shares or pre-funded warrants represent approximately 46% of the current float, a significant dilution for a micro-cap company.
Financial Strain and Going Concern Warning
The financing comes as Co-Diagnostics faces tightening liquidity. In its latest quarterly filing, the company reported $8.2 million in cash and cash equivalents as of March 31, down from $11.9 million at the end of last year. Management included a “substantial doubt” about the company's ability to continue as a going concern, a standard accounting disclosure that signals the need for additional funding or improved operational results to sustain operations.
Ebola Assay Development
On Tuesday, Co-Diagnostics announced that its assay development strategy for the Bundibugyo virus (BDBV) is now complete. CEO Dwight Egan stated that the company could “rapidly make the test available” if needed. However, the company also noted that its Co-Dx PCR platform remains under regulatory review and is not yet approved for sale. The development follows the World Health Organization's May 17 declaration of the Ebola outbreak in the DRC and Uganda as a public health emergency of international concern, though not a pandemic. The WHO warned that the outbreak may be larger than currently known, with 536 suspected cases, 34 confirmed cases, and 134 deaths reported as of May 19.
Market and Competitive Context
U.S. health officials have tightened entry restrictions and travel screening in response to the outbreak. The CDC and DHS implemented new public health measures on May 19, while cautioning that case numbers could shift. Meanwhile, competition is emerging. Reuters reported that BioFire Defense, a subsidiary of France's bioMérieux, already has an FDA-cleared test for several Ebola strains, including Bundibugyo, and is ramping up production. WHO's Anne Ancia noted that only six tests for the strain can be run per hour, highlighting testing capacity constraints.
Biotech stocks broadly edged lower before the open, with the SPDR S&P Biotech ETF slipping 0.7%. For Co-Diagnostics, sharp moves on news headlines are not uncommon but often prove short-lived. The key factors to watch are the company's ability to secure regulatory clearance, convert public health interest into actual orders, and manage its funding needs without excessive dilution.
Risk Factors
Investors should be aware of significant risks. The Ebola assay announcement is a strategy update, not a product approval or a signed contract. The new securities could substantially dilute existing shareholders if the warrants are exercised. If the outbreak response relies on already-cleared tests from competitors, or if Co-Diagnostics fails to obtain regulatory clearance and generate sales, Tuesday's rally could quickly reverse.
